The RTX pipeline consists of seven veterinary development programs, in-market dates start early 2019 and final program concludes end of 2020.

R&D

Resiniferatoxin is an interesting “pharmaceutical platform” as it has potential benefits across many species and for a diverse number of pain-triggered physiological conditions. Many indications (such as corneal ulcers in horses) would also be applicable to other species, giving a broad set of future indications to promote.

We believe we are just beginning to discover how and when to use this molecule in the pursuit of giving patients more therapeutic solutions for hard-to-treat conditions.